Oxford says TroVax offers 95% disease control in colorectal cancer

By Elaine Rigoli

Tampa, Fla., June 7 - Oxford BioMedica said TroVax plus chemotherapy in metastatic colorectal cancer showed that 95% of per protocol patients had disease control and updated survival data from the two metastatic colorectal cancer trials showed that one-third of the patients were still alive with an average follow-up time of more than two years.

The company also said data from Cancer Research UK's trial of TroVax adjuvant therapy in colorectal cancer patients undergoing surgery for liver metastases showed that 96% of patients produced an antitumor immune response and 56% of operable patients remained disease-free after nine months of follow-up.

First presentation of data from two studies of TroVax plus interleukin-2 in renal cell carcinoma showed that two of the first six evaluable patients (33%) had partial responses.

If reproduced in a larger study, this would compare favorably with a response rate of 10% for interleukin-2 alone, according to a news release.

"We are very pleased that the positive results from the phase 2 colorectal cancer trials continue to be mirrored in renal cancer. There is growing interest in TroVax amongst the clinical community in both Europe and the USA. This external support has enabled us to broaden the clinical development of TroVax," chief medical officer Mike McDonald said in the release.

Oxford BioMedica is a biopharmaceutical company located in Oxford, U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.